TIAA CREF Investment Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

TIAA CREF Investment Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$890K	Sell	187,423 -16,267	-8%	-$42.7K	﹤0.01%	2380
2018 Q4	$489K	Buy	203,690 +23,303	+13%	+$76.1K	﹤0.01%	2575
2018 Q3	$794K	Sell	180,387 -10,321	-5%	-$57.2K	﹤0.01%	2531
2018 Q2	$1.37M	Buy	+190,708	New	+$1.3M	﹤0.01%	2360
2017 Q2	–	Sell	-95,345	Closed	-$377K	–	3200
2017 Q1	$377K	Sell	95,345 -14,473	-13%	-$72.6K	﹤0.01%	2885
2016 Q4	$538K	Sell	109,818 -38,588	-26%	-$232K	﹤0.01%	2813
2016 Q3	$1.15M	Sell	148,406 -84,351	-36%	-$568K	﹤0.01%	2473
2016 Q2	$1.3M	Sell	232,757 -4,632	-2%	-$29.6K	﹤0.01%	2383
2016 Q1	$1.28M	Buy	237,389 +64,470	+37%	+$375K	﹤0.01%	2332
2015 Q4	$1.51M	Hold	172,919	–	–	﹤0.01%	2333
2015 Q3	$1.45M	Buy	172,919 +36,370	+27%	+$579K	﹤0.01%	2340
2015 Q2	$2.41M	Buy	+136,549	New	+$1.75M	﹤0.01%	2188

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

TIAA CREF Investment Management's SRNE Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Sorrento Therapeutics, Inc. (SRNE) stake by 8% in Q1 2019, selling an estimated $42.7K and leaving 187,423 shares worth $890K. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

TIAA CREF Investment Management first reported a position in SRNE in Q2 2015 and has held it in 12 quarters since. The position peaked at $2.41M in Q2 2015. 84 funds tracked by Wall St. Rank hold SRNE as of Q1 2019.

TIAA CREF Investment Management held 187,423 shares of Sorrento Therapeutics, Inc. worth $890K as of Q1 2019.
TIAA CREF Investment Management sold 16,267 Sorrento Therapeutics, Inc. shares in Q1 2019, an estimated $42.7K.
Sorrento Therapeutics, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2380 holding.
TIAA CREF Investment Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and has held it in 12 quarters since.
TIAA CREF Investment Management's Sorrento Therapeutics, Inc. position peaked at $2.41M in Q2 2015.
84 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.